{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:22:45Z","timestamp":1791958965565,"version":"4.3.4"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.1001\/jamadermatol.2021.0345","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T11:31:20Z","timestamp":1617190280000},"page":"549","source":"Crossref","is-referenced-by-count":71,"title":["Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma"],"prefix":"10.1001","volume":"157","author":[{"given":"Megan","family":"Lam","sequence":"first","affiliation":[{"name":"Michael G. DeGroote School of Medicine, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Wei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Michael G. DeGroote School of Medicine, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Drucker","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"},{"name":"Division of Dermatology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi210009r2","doi-asserted-by":"crossref","DOI":"10.5812\/ijcm.6173","article-title":"Topical calcineurin inhibitors and malignancy risk.","volume":"10","author":"Radovic","year":"2017","journal-title":"Int J Cancer Manag"},{"issue":"4_suppl","key":"doi210009r3","doi-asserted-by":"publisher","first-page":"19S","DOI":"10.1177\/1203475419857688","article-title":"What is the risk of harm associated with topical calcineurin nhibitors?","volume":"23","author":"Hanna","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"doi210009r4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjd.2005.153.issue-4","article-title":"Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?","volume":"153","author":"Ormerod","year":"2005","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi210009r7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamadermatol.2020.2239","article-title":"Topical calcineurin inhibitors and skin cancer\u2014another piece of the puzzle.","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi210009r8","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1345\/aph.1M278","article-title":"Association between exposure to topical tacrolimus or pimecrolimus and cancers.","volume":"43","author":"Hui","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"6","key":"doi210009r9","first-page":"834","article-title":"Topical calcineurin inhibitors, topical glucocorticoids and cancer in children: a nationwide study.","volume":"96","author":"Deleuran","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"doi210009r11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"15","key":"doi210009r12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"9","key":"doi210009r14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025874","article-title":"Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis.","volume":"9","author":"Eyawo","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"doi210009r15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019490","article-title":"Premenstrual syndrome and alcohol consumption: a systematic review and meta-analysis.","volume":"8","author":"Fern\u00e1ndez","year":"2018","journal-title":"BMJ Open"},{"key":"doi210009r16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijid.2014.12.016","article-title":"Tuberculosis and chronic respiratory disease: a systematic review.","volume":"32","author":"Byrne","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"1","key":"doi210009r17","first-page":"59","article-title":"Risk of venous thromboembolism in women taking the combined oral contraceptive: a systematic review and meta-analysis.","volume":"45","author":"Bateson","year":"2016","journal-title":"Aust Fam Physician"},{"issue":"1","key":"doi210009r18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12877-015-0007-2","article-title":"A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer\u2019s disease in older adults.","volume":"15","author":"Beckett","year":"2015","journal-title":"BMC Geriatr"},{"issue":"6","key":"doi210009r20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3109\/09546634.2016.1163317","article-title":"Topical calcineurin inhibitors in eczema and cancer association: a cohort study.","volume":"27","author":"Cai","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"doi210009r21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/CLEP","article-title":"A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).","volume":"10","author":"Castellsague","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"6","key":"doi210009r22","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/jamadermatol.2014.4305","article-title":"Association between malignancy and topical use of pimecrolimus.","volume":"151","author":"Margolis","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi210009r23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000209289","article-title":"Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.","volume":"219","author":"Schneeweiss","year":"2009","journal-title":"Dermatology"},{"key":"doi210009r24","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2020.2240","article-title":"Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis.","author":"Asgari","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi210009r25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi210009r26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jaci.2009.02.028","article-title":"Lymphoma among patients with atopic dermatitis and\/or treated with topical immunosuppressants in the United Kingdom.","volume":"123","author":"Arellano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"doi210009r27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/sj.jid.5700622","article-title":"Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.","volume":"127","author":"Arellano","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi210009r28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000100879","article-title":"Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.","volume":"214","author":"Margolis","year":"2007","journal-title":"Dermatology"},{"issue":"7568","key":"doi210009r29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot.","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"issue":"5","key":"doi210009r30","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/j.0022-202X.2005.23858.x","article-title":"Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation.","volume":"125","author":"Yarosh","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"23","key":"doi210009r31","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1158\/0008-5472.CAN-09-1404","article-title":"Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.","volume":"69","author":"Datta","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"doi210009r32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/phpp.v36.6","article-title":"Calcineurin inhibitor (CNI)\u2013associated skin cancers: new insights on exploring mechanisms by which CNIs downregulate DNA repair machinery.","volume":"36","author":"Ume","year":"2020","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"doi210009r33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clindermatol.2009.04.001","article-title":"Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.","volume":"28","author":"Tha\u00e7i","year":"2010","journal-title":"Clin Dermatol"},{"key":"doi210009r34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2458-4-51","article-title":"Allergic conditions and risk of hematological malignancies in adults: a cohort study.","volume":"4","author":"S\u00f6derberg","year":"2004","journal-title":"BMC Public Health"},{"issue":"5","key":"doi210009r36","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jaad.2006.01.054","article-title":"The use of topical calcineurin inhibitors in dermatology: safety concerns: report of the American Academy of Dermatology Association Task Force.","volume":"54","author":"Berger","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi210009r37","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis.","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi210009r39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjd.2011.165.issue-3","article-title":"Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.","volume":"165","author":"Tennis","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi210009r40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamadermatol.2019.3786","article-title":"Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis.","volume":"156","author":"Wang","year":"2020","journal-title":"JAMA Dermatol"},{"key":"doi210009r19","year":"2014"},{"key":"doi210009r1","unstructured":"Food and Drug Administration, Office of the Commissioner. Minutes of the Pediatric Advisory Committee meeting. February 14, 2005. Accessed August 24, 2020. https:\/\/wayback.archive-it.org\/7993\/20170404062542\/https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/minutes\/2005-4089m1_Minutes.pdf"},{"key":"doi210009r5","unstructured":"US Food and Drug Administration. Information for healthcare professionals: pimecrolimus (marketed as Elidel). Published 2006. Accessed August 24, 2020. https:\/\/wayback.archive-it.org\/7993\/20170112032734\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm153525.htm"},{"key":"doi210009r6","unstructured":"US Food and Drug Administration. FDA approves updated labeling with boxed warning and medication guide for two eczema drugs, Elidel and Protopic. Published 2006. Accessed August 24, 2020. https:\/\/wayback.archive-it.org\/7993\/20171115034557\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm153941.htm"},{"key":"doi210009r10","unstructured":"National Institute for Health Research. The association between topical calcineurin inhibitor use and risk of cancer: a systematic review and meta-analysis. CRD42020190452. Accessed August 21, 2020. https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=190452"},{"key":"doi210009r13","unstructured":"Wells? GS., O\u2019Connell? D, Peterson J, Welch V, Losos L, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Health Research Institute. Published 2019. Accessed August 1, 2020. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"doi210009r35","doi-asserted-by":"crossref","unstructured":"Zhang? Y, Holford? TR, Leaderer? B, . Prior medical conditions and medication use and risk of non\u2013Hodgkin lymphoma in Connecticut United States women.? Cancer Causes Control. 2004;15(4):419-428.  doi:10.1023\/B:CACO.0000027506.55846.5d15141141","DOI":"10.1023\/B:CACO.0000027506.55846.5d"},{"key":"doi210009r38","unstructured":"Institute for Health Metrics and Evaluation. Global Health Data Exchange. Accessed January 14, 2021. http:\/\/ghdx.healthdata.org\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2778024\/jamadermatology_lam_2021_oi_210009_1620146011.30424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T12:02:48Z","timestamp":1621425768000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2778024"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.0345","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}